Biotech Stock Soars Over 100% On Premarket Following Acquisition Announcement

By: Tomas Ronolski - AllPennyStocks.com News

Wednesday, April 30, 2025

A California-based biotech company is absolutely stealing the spotlight after it was announced that Novartis AG is set to acquire it. The press release mentions that Novartis is to acquire the company ‘for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion.’

Seeing that Regulus Therapeutics Inc. (Nasdaq:RGLS) closed at just $3.37 on Tuesday, it’s no wonder that shares of this small cap are already off to the races, with traders currently bid at $7.82/share (132.05% implied open for sellers). Be sure to keep your eye on this one!

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.